Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Shaomeng Wang
University of Michigan, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ascentage Pharma
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
see attached
Targeting the MLL-WDR5 protein-protein interaction
Acute myeloid leukemia (AML) is a form of blood cancer and affects both children and adults with an incidence of approximately 7000 new patients in the U.S. each year. A substantial portion of AML cases has extremely dire prognosis and new and effective therapies are urgently needed. This project seeks the discovery and development of small-molecule inhibitors of the WDR5-MLL protein-protein interaction as a completely new class of therapy for the treatment of AML and other types of human cancer.
Filed on May 22, 2013.
Tell us what you know about Shaomeng Wang's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Shaomeng Wang filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Shaomeng Wang | University of Michigan | Conflict of Interest | Ascentage Pharma | $80,000 - $99,999 |
| Shaomeng Wang | University of Michigan | Conflict of Interest | Ascentage Pharma | $0 - $4,999 |
| Shaomeng Wang | University of Michigan at Ann Arbor | Conflict of Interest | MedSyn Biopharm, LLC | $0 - $4,999 |
| Shaomeng Wang | University of Michigan at Ann Arbor | Conflict of Interest | MedSyn Biopharm, LLC | $0 - $4,999 |
| Shaomeng Wang | University of Michigan | Conflict of Interest | Ascentage Pharma | $0 - $4,999 |
| Shaomeng Wang | University of Michigan at Ann Arbor | Conflict of Interest | MedSyn Biopharm, LLC | $0 - $4,999 |
| Shaomeng Wang | University of Michigan | Conflict of Interest | Ascentage Pharma | $0 - $4,999 |
| Shaomeng Wang | University of Michigan | Conflict of Interest | Ascentage Pharma | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.